Business Description

Description
Rebus Hldgs Inc is an early-stage, pre-revenue, pharmaceutical company that is focused on the development of prodrug cancer therapeutics for the treatment of disease. The company along with its subsidiaries is engaged in the production of small-molecule adenosine receptor modulators. Adenosine is an extracellular signaling molecule that regulates multiple aspects of tissue function and specifically plays a role in immunity and inflammation.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.02
Equity-to-Asset -623.33
Debt-to-Equity -0.06
Debt-to-EBITDA 0.52
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 0.01
9-Day RSI 2.29
14-Day RSI 15.22
6-1 Month Momentum % -98.86
12-1 Month Momentum % -99.28

Liquidity Ratio

Name Current Vs Industry Vs History

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1470.8
Shareholder Yield % 2610

Profitability Rank

Name Current Vs Industry Vs History
ROE % Neg. Equity
ROA % 681.82
ROIC % -16.51
Years of Profitability over Past 10-Year 1

GF Value Rank

Name Current Vs Industry Vs History
PE Ratio 0.01
EV-to-EBIT 0.52
EV-to-EBITDA 0.52
EV-to-FCF -0.53
Earnings Yield (Greenblatt) % 192.31
FCF Yield % -19400